ROCE Insights For Acutus Medical
Portfolio Pulse from Benzinga Insights
Acutus Medical (NASDAQ:AFIB) reported Q1 sales of $3.59 million, with a loss of $27.83 million. The company's Return on Capital Employed (ROCE) was -0.28%, indicating inefficiency in asset utilization. Q1 earnings per share were $-0.97, missing analyst expectations of $-0.81.
May 28, 2021 | 3:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Acutus Medical's Q1 results show a loss of $27.83 million and a ROCE of -0.28%, indicating inefficiency in asset utilization. The EPS of $-0.97 missed analyst expectations, which may negatively impact short-term stock prices.
The significant loss and negative ROCE suggest inefficiency in asset utilization, which is a concern for investors. Missing EPS expectations further adds to the negative sentiment, likely impacting the stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100